Can't fill your Amjevita prescription? Explore FDA-approved alternatives including other adalimumab biosimilars and TNF inhibitors that treat the same conditions.
If you've been prescribed Amjevita (Adalimumab-Atto) but can't fill your prescription — whether because of cost, availability, or insurance issues — you have options. Several FDA-approved alternatives work the same way and treat the same conditions.
Before switching medications, always talk to your doctor. But knowing what's out there can help you have a more productive conversation with your healthcare team. This guide covers the most common alternatives to Amjevita available in 2026.
Amjevita is a biosimilar to Humira (Adalimumab), made by Amgen. It was the first Humira biosimilar to launch in the U.S. in January 2023. The active ingredient, Adalimumab-Atto, is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), a protein that drives inflammation in autoimmune diseases.
By neutralizing TNF-α, Amjevita reduces inflammation and helps control symptoms of conditions like rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and more. For a deeper dive, read our guide to how Amjevita works.
Because Amjevita is a biosimilar, its alternatives fall into two main categories: other Adalimumab biosimilars (which are nearly identical) and other TNF inhibitors (which work through a similar mechanism but are different drugs).
The easiest switch from Amjevita is to another Adalimumab biosimilar. These medications contain a version of Adalimumab that has been shown to have no clinically meaningful differences from the reference product (Humira). They treat all the same conditions and are dosed the same way.
Manufacturer: Organon / Samsung Bioepis
Hadlima is an Adalimumab biosimilar available in prefilled syringes and autoinjector pens. It's approved for all the same indications as Amjevita and Humira. Hadlima has gained formulary preference with several major insurance plans, which means it may be easier to get covered and find in stock compared to other biosimilars.
Key difference: Hadlima may be your insurer's preferred Adalimumab product. If Amjevita isn't covered, Hadlima might be.
Manufacturer: Sandoz
Hyrimoz is another interchangeable Adalimumab biosimilar, meaning pharmacists can substitute it for Humira without a new prescription in most states. The high-concentration (HC) citrate-free version of Hyrimoz has been gaining market share. Several PBMs and insurance plans have placed Hyrimoz on preferred formulary tiers.
Key difference: Hyrimoz HC (high-concentration, citrate-free) offers the same injection convenience as Amjevita and may be preferred by your insurance plan.
Manufacturer: Boehringer Ingelheim
Cyltezo was the first Adalimumab biosimilar to receive FDA interchangeability designation. It's available in both branded and unbranded versions. The unbranded Adalimumab-Adbm is often one of the lowest-cost options, with GoodRx prices significantly below brand-name Humira.
Key difference: Cyltezo and its unbranded version can be among the most affordable Adalimumab options, especially for cash-pay patients.
Manufacturer: Teva
Simlandi is a newer Adalimumab biosimilar that entered the market more recently. It's available in a high-concentration, citrate-free autoinjector pen and prefilled syringe. As a newer entrant, Simlandi may offer competitive pricing and savings programs.
Key difference: As a newer biosimilar, Simlandi may have aggressive copay assistance programs for patients switching from other products.
If Adalimumab biosimilars aren't working for you — because of side effects, insurance restrictions, or other reasons — your doctor may consider a different TNF inhibitor. These are not biosimilars to Humira; they are separate biologic drugs that also block TNF-α but have different molecular structures.
Enbrel is a TNF inhibitor that works differently from Adalimumab — it's a fusion protein rather than a monoclonal antibody. It's FDA-approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and juvenile idiopathic arthritis. Enbrel is typically injected once or twice weekly.
Note: Enbrel is not approved for Crohn's disease or ulcerative colitis, so it's only an alternative for certain conditions.
Infliximab is another TNF inhibitor, but it's administered as an intravenous (IV) infusion rather than a subcutaneous injection. It's approved for rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Several Infliximab biosimilars are available, including Inflectra and Renflexis.
Note: Because Infliximab requires IV infusions (usually every 6-8 weeks at an infusion center), it's a bigger lifestyle change compared to self-injecting at home with Amjevita.
When choosing an alternative to Amjevita, consider these factors:
If you can't fill your Amjevita prescription, you're not out of options. Multiple Adalimumab biosimilars are available that work the same way and treat the same conditions. For some patients, a different TNF inhibitor might be the better choice.
Start by checking with your insurance to see which products are covered, then use Medfinder to locate available options near you. And always talk to your doctor before making any changes to your treatment. Staying on an effective biologic therapy is the most important thing — the specific brand is secondary.
For more information, read our guides on what Amjevita is and how it's used and how to find Amjevita in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
